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Impact of Lymphovascular Invasion on Overall
Survival in Patients With Prostate Cancer
Following Radical Prostatectomy: Stage-per-Stage
Analysis
Marcus Jamil,1 Nikola Rakic, BS,1 Akshay Sood,1 Jacob Keeley,1
Daniele Modonutti,1 Giacomo Novara,2 Wooju Jeong,1 Mani Menon,1
Craig G Rogers,1 Firas Abdollah, MD1
ABSTRACT
The detrimental impact of lymphovascular invasion (LVI) in prostate cancer on biochemical recurrence has been
described; the impact of LVI on overall survival remains unclear. In this study, we determined that patients with
LVI identiﬁed on ﬁnal pathology after radical prostatectomy fared worse than those without.
Background: The detrimental impact of lymphovascular invasion (LVI) in prostate cancer (PCa) on biochemical recurrence has been described; the impact of LVI on overall survival (OS) remains unclear. This investigation sought to
evaluate the impact of LVI on OS in patients with PCa. Methods: We examined men with nonmetastatic PCa treated
with radical prostatectomy between 2010 and 2015. Only men with documented LVI status were included (n = 232,704).
Patients were stratiﬁed according to ﬁnal pathologic T stage (pT2, pT3a, and pT3b). Results: Of the 232,704 patients
who met inclusion criteria, 17,758 (8%) were found to have LVI on ﬁnal pathology. Overall, 174,838 (75%), 40,281 (17%),
and 17,585 (8%) patients had pT2, pT3a, and pT3b disease, respectively. Median follow-up was 42.7 months (27.1-58.7).
At 5 years, the OS in LVI versus non-LVI patients was 94% versus 95% in pT2 (P = .0004), 92% versus 95% in pT3a
(P < .0001), and 86% versus 92% in pT3b (P < .0001). On multivariable analysis, LVI status was not an independent
predictor of OS in pT2 disease (hazard ratio, 1.12; 95% conﬁdence interval [CI], 0.93-1.36; P = .2). In pT3a and pT3b
disease, presence of LVI had 1.2-fold (95% CI, 1.03-1.44; P = .02) and 1.4-fold (95% CI, 1.20-1.59; P < .001) higher
overall mortality than their counterparts without LVI. Conclusions: Our report demonstrates the detrimental impact of
LVI on OS in locally advanced PCa (pT3a and higher). This information may prove valuable when risk stratifying based
on ﬁnal pathology.
Clinical Genitourinary Cancer, Vol. 19, No. 5, e319–e325 © 2021 Published by Elsevier Inc.
Keywords: Locally advanced prostate cancer Lymphovascular Invasion, Pathologic staging, Prostatic neoplasms,
Prostatectomy

Introduction
Prostate cancer (PCa) is the most commonly diagnosed solid
organ malignancy and the second leading cause of cancer-specific
mortality in men within the United States, with an estimated
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191,930 new diagnosis and 33,330 deaths in 2020.1 Clinical
and pathologic staging are integral in assigning risk-stratification
and determining appropriate treatment.2 , 3 Of the available treatments, radical prostatectomy remains one of the most commonly
performed interventions for patients with clinically localized PCa.4
Despite the many advances in the treatment of PCa; the rates of
biochemical recurrence (BCR) remain high, with estimations of
20% to 30%,5 , 6 Therefore, it remains of paramount importance
to identify those pathologic features that increase a patient’s risk
of recurrence, because it is expected that more high-risk and more
locally advanced disease is to be identified in the coming years with
the 2012 US Preventative Task Force’s recommendations against
routine prostate-specific antigen (PSA) screening owing to concerns
of overtreatment.7
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Impact of Lymphovascular Invasion on Overall Survival
Lymphovascular invasion (LVI) has been recognized as an adverse
pathologic feature, estimations on the incidence differ widely,
between 5.1% and 46.3% of patients with prostate cancer who
undergo radical prostatectomy are found to have LVI on final
pathology.8 Various investigations have demonstrated the association between LVI and higher PSA, higher Gleason score, more
advanced stage, higher rate of lymph node involvement and a higher
risk of BCR.6 , 9-14 However, the impact of LVI on overall survival
(OS) has been scarcely addressed in the literature and remains
unclear, with a majority of the focus primarily on the effect of LVI
on BCR-free survival, which may not necessarily be a good surrogate for OS.15-17 Finally, although few studies have assessed the role
of LVI as an adverse prognostic factor in pT3 patients, no studies
have assessed its prognostic impact in PCa of other stages.12 , 13 Our
objective was, therefore, to evaluate the prognostic capacity of LVI
as a predictor of OS stratified by pathologic tumor stage.

Materials and Methods
Study Population
Data were obtained from the National Cancer Database, a
national registry that is jointly sponsored by American Cancer
Society and the Commission on Cancer of the American College of
Surgeons, which captures approximately 70% of newly diagnosed
malignancies within the United States annually. The National
Cancer Database extracts data from more than 1500 commissionaccredited cancer programs in the United States.18
Within the National Cancer Database, we identified a total
of 232,704 patients with histologically confirmed nonmetastatic
adenocarcinoma of the prostate who were treated with radical
prostatectomy between 2010 and 2015. Patients before 2010 were
excluded, owing to a lack of recorded LVI status within the National
Cancer Database. Complete inclusion and exclusion criteria are
detailed in Fig. 1.

Covariates
The following variables were extracted for all patients: age at
diagnosis, race (Caucasian, African American, and other), serum
PSA value at diagnosis, Charlson Comorbidity Index category (0,
1, or ≥2), pathologic tumor stage (pT2, pT3a, or pT3b), pathologic Gleason score (≤6, 3 + 4, 4 + 3, or 8-10), surgical margin
status (negative or positive), number of nodes examined, number of
positive nodes, pathologic nodal status (pN0 or pN1 ), and pathologic LVI status (pL0 or pL1 ). LVI was defined as the presence
of tumor cells in lymphatic channels or blood vessels within the
primary tumor.18

End Points
The primary end point investigated in this study was OS, which
was defined as the months between diagnosis and death owing to
any cause, or last available follow-up. Follow-up data were available
through December 21, 2016.

Statistical Analyses
Frequencies and proportions were reported for categorical
variables, while medians with interquartile ranges were reported for
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continuous variables. The χ 2 and Mann-Whitney U tests were used
to compare categorical and continuous variables, respectively.
After stratification of patients based on LVI status, Kaplan-Meier
curves were used to estimate OS. Next, Cox regression analyses
were used to test the relationship between LVI status and OS using
all available covariates. These analyses were repeated in all subcohorts after stratifying for pathologic stage. All statistical analyses
were performed using SAS 9.4 (SAS Institute, Cary, NC). Two-sided
statistical significance was defined as a P value of less than .05. An
institutional review board waiver was obtained before the study was
conducted, in accordance with institutional regulation when dealing
with de-identified, previously collected data.

Results
Descriptive characteristics of our cohort are reported in Table 1.
The median age (interquartile range) and PSA for all patients was
62 years (56-67 years) and 5.6 ng/mL (4.3-8.2 ng/mL), respectively.
The median (interquartile range) follow-up was 42.7 months (27.158.7 months). Most patients had pT2 disease (75%). Gleason score
(3 + 4) was the most frequently identified Gleason score (44%). A
total of 17,758 patients (8%) had LVI identified on final pathology.
Patients with LVI had higher rates of Gleason score of 8 to 10 (43%
vs 8%; P < .0001), higher pathologic tumor stage (pT3b, 31% vs
4%; P < .0001) and higher rates of lymph node involvement (20%
vs 1%; P < .0001) than their counterparts without LVI.
At 5 years, the OS in LVI versus non-LVI were 94% versus 95% in
pT2 (P = .0004), 93% versus 95% in pT3a (P < .0001), and 86%
versus 92% in pT3b (P < .0001), respectively (Fig. 2). A time to
event analysis is available in Supplementary Table 1. On multivariable analysis, in all patients LVI status was an independent predictor
of OS (hazard ratio, 1.41; 95% confidence interval [CI], 1.22-1.61;
P < .001). When assessing specific stages of disease, LVI status was
not an independent predictor of OS in pT2 disease (hazard ratio,
1.12; 95% CI, 0.93-1.36; P = .2). However, in pT3a and pT3b
disease, the presence of LVI had a 1.2-fold (95% CI, 1.03-1.44;
P = .02) and 1.4-fold (95% CI, 1.20-1.59; P < .001) higher overall
mortality than their counterparts without LVI (Table 2).

Discussion
The objective of our study was to assess the impact of LVI on
OS in patients who underwent radical prostatectomy for clinically
localized PCa using a large contemporary cohort of North American patients. Historically, some investigations have attempted to
evaluate the impact of LVI on oncological outcomes, these findings
have frequently been inconsistent. This phenomenon may have been
due to the recent standardization of LVI reporting by the International Society of Urological Pathology in 2009.19 More contemporary reports assessing the outcomes of patients with LVI on final
pathology have focused primarily on BCR, a parameter that has not
been shown to be an ideal surrogate for OS in patients with prostate
cancer.15-17 Thus, our study aimed to address an important void in
the literature by focusing on OS as an end point.
The results of our analysis were able to provide insight into the
effects of LVI on patients with PCa according to pathologic tumor
stage. The rate of LVI within the present study was 8%, which lies
within the lower end of the variable range of the reported rates
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1

Patient selection flow diagram. LVI = lymphovascular invasion; PCa = prostate cancer; NCDB = National Cancer
Database.

within the literature.6 , 8 , 10 , 20 , 21 At 5 years, the OS in LVI versus nonLVI patients was 94% versus 95% in pT2 (P = .0004), 93% versus
95% in pT3a (P < .0001), and 86% versus 92% in pT3b (P <
.0001). This deleterious impact of LVI on OS was most pronounced
for patients with pT3b disease who demonstrated a 1.4-fold (95%

CI, 1.20-1.59; P < .001) higher overall mortality than patients with
pT3b without LVI. In an investigation conducted by Park et al,12
the authors assessed patients with both LVI and seminal vesical
invasion (SVI), patients with +LVI/+SVI were shown to have a far
worse 5-year BCR-free survival rate compared with patients with
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Impact of Lymphovascular Invasion on Overall Survival
Table 1

Descriptive Characteristics of All 232,704 Patients Identified Within the National Cancer Database Stratified by the
Presence or Absence of LVI on Final Pathologic Specimen.

Characteristics

Entire Cohort

No LVI

LVI

P Value∗

62 (56-67)

62 (56-67)

63 (57-67)

<.0001

5.6 (4.3-8.2)

5.5 (4.3-7.9)

7.3 (5-12.6)

.01

Caucasian

193,842 (83%)

178,898 (83%)

14,944 (84%)

ref

AA

29,328 (13%)

27,196 (13%)

2,132 (12%)

<.0001
.002

Age
Median PSA† (IQR)
Race

Other

6556 (3%)

6053 (3%)

503 (3%)

Missing

2978 (1%)

2799 (1%)

179 (1%)

0

190,569 (82%)

176,372 (82.1%)

14,197 (80%)

ref

1

36,781 (16%)

33,657 (15.7%)

3124 (17.6%)

<.0001

2

5354 (2%)

4917 (2.3%)

437 (2.5%)

<.0001

CCI

Gleason Score
≤6

63,631 (27%)

62,799 (29%)

832 (5%)

ref

3+4

103,030 (44%)

98,872 (46%)

4,158 (23%)

.0002

4+3

37,052 (16%)

32,250 (15%)

4,802 (27%)

.009

8-10

24,859 (11%)

17,187 (8%)

7,672 (43%)

<.0001

Missing

4132 (2%)

LVI status

3838 (2%)

294 (2%)

214,946 (92%)

17,758 (8%)

.5

pTstage
pT2

174,838 (75%)

169,615 (79%)

5223 (29%)

ref

pT3a

40,281 (17%)

34,730 (16%)

5551 (31%)

.007

pT3b

17,585 (8%)

10,601 (5%)

6984 (39%)

<.0001

pN0

138,045 (59%)

127,236 (59%)

10,809 (61%)

ref

pN1

6129 (3%)

2617 (1%)

3512 (20%)

<.0001
0.2

pNstage

pNX
Missing
Nodes examined

50,535 (22%)

48,764 (23%)

1771 (10%)

37,995 (16%)

36,329 (17%)

1666 (9%)

3 (0-7)

3 (0-7)

5 (2-10)

<.0001

Surgical margins
Positive

50,468 (22%)

42,904 (20%)

7564 (43%)

Negative

179,388 (77%)

169,425 (79%)

9963 (56%)

Unknown

2848 (1%)

2617 (1%)

231 (1%)

AA = African American; CCI = Charlson Comorbidity Index; IQR = interquartile range; LVI = lymphovascular invasion; PSA = prostate-speciﬁc antigen (∗ ng/mL); ref = reference.
∗
The χ 2 P values refer to the comparison between patients with and without LVI in each respective clinical and pathologic parameter.

+LVI/–SVI, –LVI/+SVI or –LVI/–SVI (22.4%, 42.8%, 54.1%,
and 61.5%, respectively). Although the primary outcomes between
the referenced study and the present study are different, namely
BCR versus OS, these findings reinforce the premise that patients
with LVI in higher stage disease fare worse. The same authors also
observed, through random survival Forest analysis modeling, that
LVI was one of the most important predictors of BCR in patients
with pT3 disease, second only to Gleason grade, further highlighting the importance of LVI.12
The implications of our findings are 2-fold. First, it aids
providers with the necessary information to council patients
on overall outcomes after radical prostatectomy, for one could
only extrapolate rates of BCR and lymph node involvement in
patients with LVI given the available literature.6 , 9 , 12-14 LVI is a
readily available pathologic finding that could be added to the
armamentarium of providers, alongside other new prognostic tools,
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biomarkers, and genomic tests. Second, these findings may be
used as a point of reinforcement when deciding which patients
may require adjuvant treatment for marginal cases. Similar to
our investigation, Fajkovic et al6 investigated a cohort of 7427
patients treated by radical prostatectomy between 2000 and 2011
and identified that LVI was associated with BCR in patients with
adverse pathologic features such as extracapsular extension, SVI,
and a higher Gleason grade versus patients with a lower Gleason
grade (Gleason grade 6) and organ-confined disease. Ultimately, the
authors suggest possibly using LVI as a marker to decide which of
these higher risk patients warrant adjuvant treatment. Given the
multitude of investigations which have demonstrated worse BCRfree survival in patients with LVI and higher risk disease, and
the present investigation demonstrating worse OS in patients with
positive LVI status, this notion is consistent with the present authors
opinions6 , 9 , 11-14 , 20 , 21
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Table 2

Five-year overall Kaplan-Meir survival analysis for all 232,704 patients after radical prostatectomy with and without
lymphovascular invasion on final pathology stratified by pathologic tumor stage. pTstage = pathologic tumor stage;
LVI = lymphovascular invasion; OS = overall survival.

Cox Multivariable Regression Predicting Overall Survival in All 232,704 Patients Identified Within the National Cancer
Database Diagnosed With Prostate Cancer With Documented Presence or Absence of LVI on Final Pathologic Specimen
Stratified by Pathologic Tumor Stage.
pT2

pT3a

pT3b/pT4
HR (95%
Confidence
Interval)

HR (95%
Confidence
Interval)

P Value

HR (95%
Confidence
Interval)

P Value

1.08 (1.08-1.09)

<.0001

1.05 (1.04-1.06)

<.0001

1.03 (1.02-1.04)

<.0001

AA

1.37 (1.23-1.53)

<.0001

1.23 (1.0-1.5)

.04

1.08 (0.87-1.34)

.5

Other

0.68 (0.51-0.90)

.009

0.77 (0.51-1.15)

.2

0.82 (0.54-1.23)

.4

Age

P Value

Race

Caucasian

ref

ref

ref

CCI
≥2

2.73 (2.3-3.2)

<.0001

3.18 (2.50-4.06)

<.001

2.05 (1.50-2.84)

<.001

1

1.64 (1.5-1.8)

<.001

1.80 (1.50-2.05)

<.001

1.51 (1.30-1.76)

<.001

1.0 (0.99-1.00)

.1

1.05 (1.04-1.06)

.0007

1.00 (1.00-1.01)

.01

3+4

0.85 (0.77-0.92)

<.0001

1.17 (0.86 -1.59)

.3

0.55 (0.30-1.11)

.07

4+3

0.87 (0.77-0.98)

.02

1.26 (0.92-1.73)

.2

0.67 (0.38-1.37)

.2

8-10

1.02 (0.88-1.19)

.8

1.80 (1.31-2.50)

.0003

1.48 (0.86-3.04)

.2

3+3

ref

0
PSA
Gleason Grade

ref

ref

Pathologic N stage
pN1

1.58 (1.14-2.20)

.006

1.19 (0.93-1.52)

.2

1.50 (1.20-1.71)

<.0001

pNX

1.04 (0.95-1.14)

.4

0.91 (0.75-1.11)

.4

0.84 (0.63-1.10)

.2

pN0

ref

ref

ref

1.03 (1.02-1.04)

<.0001

0.99 (0.99-1.01)

.8

0.99 (0.97-1.00)

.009

Positive

1.12 (0.93-1.36)

.2

1.22 (1.03- 1.44)

.02

1.41 (1.22-1.61)

<.0001

Negative

ref

Nodes examined
LVI

ref

ref

Surgical margins
Positive

0.99 (0.89-1.09)

Negative

ref

.8

1.18 (1.04-1.34)
ref

.009

1.31 (1.14-1.50)

<.0001

ref

AA = African American; CCI = Charlson Comorbidity Index; HR = hazard ratio; LVI = lymphovascular invasion; PSA = prostate-speciﬁc antigen; ref = Reference.
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Impact of Lymphovascular Invasion on Overall Survival
Our investigation is not without limitations; we acknowledge the
limitations of using a large database such as the National Cancer
Database, which could potentially result in a potential overpowering given the large sample size. Second, our analysis was preformed
retrospectively and lacked centralized pathologic review. This limitation may contribute to either an overestimation or underestimation
of the rates of LVI in radical prostatectomy specimens. It has been
reported previously that processing artifacts may mimic LVI, and
only unequivocal cases of LVI should be reported as so.6 , 22 , 23 Therefore, it may be difficult to ascertain the impact of a lack of centralized pathologic review and hence the use of a large cohort may
represent more of a realistic representation of the general population. Third, the median follow-up in our cohort was 42.7 months
and, given the natural disease progression of PCa, this relatively
short follow-up period may not truly capture the long-term negative
implications of LVI on OS. Furthermore, when assessing characteristics that may also contribute to worsening OS in such a short
follow-up period, factors such as pathologic lymph node status was
not seen to be significant in patients with pT3a disease, as it was in
patients with pT3b disease, which may be contrary to the available
literature. This result may have been in fact the result of the shortened follow-up. Last, our investigation is unable to provide information regarding any potential treatment’s patients received postoperatively.
That said, our investigation, to our knowledge, is one of the first
to provide insight into the negative effects of LVI on OS, and the
first to stratify the impact of LVI on OS by pathologic stage. This
information may prove essential in counseling patients regarding the
potential outcomes after radical prostatectomy and may augment
the discussion between physicians and patients in regard to adjuvant
treatment in high risk PCa.

Conclusion
Our report demonstrates the detrimental impact of LVI on OS in
locally advanced prostate cancer (pT3a and higher). This information may prove valuable when risk stratifying patients based on final
pathology and counseling patients regarding outcomes and determining the necessity of further treatment.

Clinical Practice Points
• Lymphovascular invasion (LVI) has been recognized as an adverse
pathologic feature. Various investigations have demonstrated the
association between LVI and higher prostate-specific antigen, a
higher Gleason score, more advanced stage, higher rate of lymph
node involvement and higher risk of biochemical recurrence.
• The impact of LVI on overall survival has been scarcely addressed
in the literature and remains unclear, with a majority of the focus
primarily on the effect of LVI on biochemical recurrence-free
survival, which may not necessarily be a good surrogate for overall
survival.
• Our report demonstrates the detrimental impact of LVI on overall
survival in locally advanced prostate cancer (pT3a and higher).
• This information may prove valuable when risk stratifying based
on final pathology and counseling patients regarding outcomes
and determining the necessity of further treatment.
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